Invivoscribe Technologies, Inc., is a privately-held corporation dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for molecular research, molecular diagnostics, and personalized molecu […
We are hiring for multiple openings in our R&D department(s) at our company!!!
We are looking for candidates with a biochem/molecular/micro background to assist the scientific staff in carrying out research assignments involving a variety of laborat […]
Top Three Skills: liquid protein formulations, drug delivery methods, analytical chemistry
Job Description: Responsible for leading fo […
Interoperability and usability headline the global availability of Visage 7.1.8
SAN DIEGO, June 22, 2016 /PRNewswire/ — Visage Imaging, Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they will be exhibiting at the Society of Imaging Informatics in Medicine 2016 Annual Meeting (SIIM 2016, Portland, OR, June 29-July 1, Booths #501/503), demonstrating Visage 7.1.8, the latest release of the Visage® 7 Enterprise Imaging Platform. Visage 7 enables enterprise imaging with amazingly fast, thin-client, server-side processing technology, as well as simple diagnostic mobile access via Visage Ease Pro®.
Visage 7 is the industry’s leading enterprise diagnostic viewer for healthcare’s most acclaimed institutions. While many vendors struggle to complete new releases bi-annually, Visage customers have experienced the prolific benefits of customer-focused Agile development. In less than five years since RSNA 2011, Visage 7 has been carefully refined with over 4,200 enhancements and fixes, comprising a staggering 35 minor releases and 8 major releases.
Visage 7.1.8 prominently features more than 150 robustness, performance and usability refinements, including the following:
- Privacy Mode – live, dynamic anonymization of the Study Browser and View Screen (Viewer and Study Navigator) for enhanced PHI protection and compliance in ad-hoc demonstration situations.
- Breast Imaging – sweep mode for digital breast tomosynthesis (DBT); DBT position indicator displays frame position in the DBT stack and scanned orientation to the coronal plane; slice thickness can be adjusted while browsing DBT; and configurable multi-level toggle sequencing of viewer text (also available for all modalities).
- Protocols and Study Layouts – further improvements to the already strong multi-modality hanging protocol and layout engine adding even more flexibility and ease of use; enhanced drag-and-drop of multi-modality imaging series into tiled layouts; ad-hoc creation of any layout orientation(s).
- Brain Perfusion – results layout of colorized series via DICOM Presentation State; and user definable exclusion of time-steps from the analysis.
- MPEG4 – enhanced handling of movies and CINE clips including native export of MPEG4 clips from embedded movie objects.
- Enhanced DICOM – support for 3D Enhanced Ultrasound images.
- Messaging – administrators are able to message all active thin-client user sessions.
The release also offers interoperability using the following Integrating the Healthcare Enterprise (IHE) profiles successfully validated at IHE Europe Connectathon 2016: Digital Breast Tomosynthesis (DBT), Image Object Change Management (IOCM), and Cross Enterprise Clinical Documents Share (XDS.b).
Malte Westerhoff, PhD, Co-founder and Global CTO of Visage Imaging explained, “Visage is focused on results. Just two months after the Connectathon, Visage 7.1.8 has been released with proven interoperability and numerous customer-driven enhancements. Confidence and capability are not meaningless buzzwords, they are standard features with Visage 7.”
Visage is proud to be part of the SIIM 2016 scientific program. Dr. Westerhoff will be speaking at “Communication and Collaboration Using Enterprise Viewers in the EMR,” SIIM 2016 Industry Insights, on Wednesday, June 29 from 9:45 am-10:45 am.
To learn more about Visage 7.1.8, please schedule a priority meeting and/or demonstration at SIIM 2016.
About Visage Imaging, Inc.
Visage Imaging is a global provider of enterprise imaging and advanced visualization solutions for diagnostic imaging. Visage 7 delivers amazingly fast server-side rendered images streamed via an intelligent thin-client viewer. Radiologists and referring physicians have a customized, protocol-driven workflow to natively view multi-dimensional imagery across a single desktop. Powerful imaging solutions include enterprise viewing and interpretation; image enablement of EHRs, VNAs, HIEs and portals; RIS/PACS, as well as anywhere mobile diagnostic access. www.visageimaging.com
About Pro Medicus Limited
Pro Medicus Limited [ASX: PME] is Australia’s leading imaging IT provider. Founded in 1983, the company provides a full range of integrated software products and services to hospital, imaging centers and health care groups worldwide. www.promed.com.au
Visage, Visage Imaging, Visage Ease Pro, Visage Ease, ANV, and Deconstructed PACS are trademarks, registered trademarks and service marks that are licensed by Visage Imaging Inc. Other product and company names mentioned may be trademarks and/or registered trademarks of their respective owners or licensees.
SOURCE Visage Imaging, Inc.
SAN DIEGO, June 22, 2016 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced two presentations at ISSCR 2016 Annual Meeting. ISSCR 2016, the Global Stem Cell Event, is taking place June 22nd to 25th at Moscone West in San Francisco.
Details of the presentations are as follows:
Focus Session: Tools for Basic and Applied Stem Cell Biology – Panel discussion on pluripotent stem cell-based therapies
Dr. Kevin D’Amour, Vice President, Research, and Chief Scientific Officer
June 22, 11:00 a.m. to 12:00 p.m. PDT
In vitro generation of insulin producing cells with insulin secretion kinetics and mitochondrial respiration similar to adult human islets [Poster T2190]
Dr. Alireza Rezania, Senior Director, Discovery
June 23, 7:00 p.m. to 8:00 p.m., PDT
The work on insulin-producing cells with characteristics of mature human beta cells that is being reported in the poster presentation originated within the Janssen BetaLogics group. In February 2016, the assets of the Janssen BetaLogics group were consolidated into ViaCyte.
“The results being presented at ISSCR demonstrate the continued progress we are making towards the development of important new treatments for insulin-dependent diabetes,” said Paul Laikind, PhD, President and CEO of ViaCyte. “In particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell-derived cell replacement therapy.”
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte has two products in development. PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired awareness of hypoglycemia. The PEC-EnCap (formerly VC-01™) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
For more information on the clinical trial, called STEP ONE, please visit https://clinicaltrials.gov/ct2/show/NCT02239354.
SOURCE ViaCyte, Inc.
Rosa & Co. and MathWorks Host Joint Webinar Discussion on How MATLAB and SimBiology Facilitate Quantitative Systems Pharmacology (QSP) Modeling and Analysis to Support Drug Development
SAN CARLOS, Calif., June 22, 2016 /PRNewswire/ — Rosa & Co. LLC, the leading commercial drug development advisory firm with expertise in QSP/PhysioPD™, today announced their participation in a joint webinar on July 13th, 2016 at 10:00 am and 2:00pm EDT with MathWorks, a developer of mathematical computing software and maker of MATLAB and SimBiology. QSP/PhysioPD approaches aim to predict the safety and therapeutic impact of a drug by quantifying the dynamics of its interactions with underlying pathophysiology in order to guide and support drug development. This webinar will use a rheumatoid arthritis (RA) PhysioPD™ Research Platform developed by Rosa & Co to illustrate the utility of key features of MATLAB and SimBiology in exploring pharmaceutical research questions.
Christina Friedrich, PhD, Chief Engineer, Rosa & Co.
Fulden Buyukozturk, PhD, Technical Evangelist, MathWorks Inc.
Webinar: MATLAB and SimBiology facilitate QSP modeling and analysis to support drug development
Wednesday, July 13th, 2016; 7:00 a.m. and 11:00 a.m. PT | 10:00 a.m. and 2:00 p.m. ET
Registration is required, though there is no charge to join.
Rosa supports clients with their critical decisions – from preclinical through clinical development – by creating and using customized PhysioPD™ Research Platforms that connect mechanisms to outcomes. PhysioPD Platforms are Quantitative Systems Pharmacology models used to simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Rosa’s clients are involved in Platform creation, testing, and biological simulation research. Clients retain the Platform as a program asset to support decisions and future research. Rosa’s staff has unparalleled professional experience applying biological modeling and simulation research to accelerate drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area experience, including metabolic diseases, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system disorders, dermatology, rare disease, and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html.
MathWorks is the leading developer of mathematical computing software. MATLAB, the language of technical computing, is a programming environment for algorithm development, data analysis, visualization, and numeric computation. Simulink is a graphical environment for simulation and Model-Based Design for multidomain dynamic and embedded systems. Engineers and scientists worldwide rely on these product families to accelerate the pace of discovery, innovation, and development in automotive, aerospace, electronics, financial services, biotech-pharmaceutical, and other industries. MATLAB and Simulink are also fundamental teaching and research tools in the world’s universities and learning institutions. Founded in 1984, MathWorks employs more than 3500 people in 15 countries, with headquarters in Natick, Massachusetts, USA. For additional information, visit mathworks.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
MATLAB and Simulink are registered trademarks of The MathWorks, Inc. See mathworks.com/trademarks for a list of additional trademarks. Other product or brand names may be trademarks or registered trademarks of their respective holders.
SOURCE Rosa & Co.
Radicle, a new accelerator fund focused on agricultural ventures, is launching today with plans to seed and nurture the next generation of agtech companies addressing global farming problems. The new…
[[Click headline to continue reading.]]
SAN DIEGO, June 22, 2016 /PRNewswire/ — Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed a testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced the formation of their scientific advisory board (SAB). Approved by the executive leadership team and board of directors, the SAB is chartered to advise on the development and commercialization of Mesa Biotech’s infectious disease assay platform. Led by Dr. Steve Young, this world-class team brings Mesa Biotech more than 120 years of combined experience in infectious diseases and molecular diagnostics.
“We are thrilled to have such a talented and experienced scientific advisory board providing critical expertise to the Mesa Biotech team,” said Hong Cai, co-founder and CEO. “The background and experience of our advisory board is going to be invaluable as we commercialize our current technology for the rapid testing of influenza A/B, as well as to help us successfully reach our goal of bringing transformative diagnostics to the point of care.”
The inaugural members of Mesa Biotech scientific advisory board include:
- Dr. Steve Young, director of research and clinical trials at TriCore Reference Laboratory, will chair the SAB. Dr. Young has completed over 100 FDA in vitro diagnostic device trials/market evaluations. He is also chairman, virology standards of the American Board of Medical Microbiology and holds a Ph.D. from the University of New Mexico.
- Dr. Angela Caliendo is professor and vice-chair of medicine and vice-president of university medicine at the Alpert Medical School of Brown University. She brings extensive virology and molecular diagnostics experience to the SAB. Currently she chairs the microbiology medical devices panel at FDA and the Diagnostics Task Force for the Infectious Diseases Society of America (ISDA). Dr. Caliendo obtained her M.D. and Ph.D. in biochemistry from Case Western University.
- Dr. Jeanne A. Jordan is a professor, George Washington University and director of GWU’s International Institute for Public Health Laboratory Management. She has extensive clinical microbiology, laboratory medicine and virology expertise. Dr. Jordan is the chair of the Infectious Disease Division of the Association for Molecular Pathology and serves on the editorial board of the Journal of Clinical Virology. Dr. Jordan obtained her Ph.D. from the University of Pittsburgh.
- Dr. James Nichols is a professor of pathology, microbiology, and immunology and medical director, clinical chemistry for the Vanderbilt University School of Medicine. He is Board certified in clinical and toxicological chemistry and has extensive evidence-based medicine, information management, lab automation, POC testing and toxicology experience. He also served as a member on CDC’s clinical laboratory improvement advisory committee. Dr. Nichols holds a Ph.D. in biochemistry from the University of Illinois.
- Dr. Stephen Day is an experienced IVD consultant. He is a member of the Expert Panel on Molecular Methods for the Clinical Laboratory Standards Institute and has extensive experience in virology and molecular diagnostics. He is on the Professional Relations Committee of the Association for Molecular Pathology and has also held other elected positions within that organization. Dr. Day received his Ph.D. in microbiology/immunology/molecular biology from the University of South Alabama.
- Dr. Chris Myers is a virologist and biosurveillance department head for the Naval Health Research Center. His team evaluates diagnostics for infectious disease targets and biowarfare/biothreat agents in clinics and operational settings and is responsible for respiratory and enteric disease surveillance in military populations. Dr. Myers received his Ph.D. from the University of Texas.
About Mesa Biotech Inc.
Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech’s diagnostic system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to obtain actionable, laboratory-quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa’s technology development has been funded to date by a series of grants and private equity investments totaling approximately $30 million. The company is preparing for Series A funding in 2016 and expects to obtain FDA approval for its first product, an influenza assay and dock, in 2017. For more information visit http://www.mesabiotech.com.
SOURCE Mesa Biotech Inc.
SENIOR RESEARCH ASSOCIATE – PRE-CLINICAL DRUG DISCOVERY – Sorrento Therapeutics, Inc. – San Diego, CA
Earn a competitive salary that allows you to focus your attention on your passion for science. If you’re a quick learner, enjoy working in the biotech industry,…
From DeviceSpace.com – 22 Jun 2016 06:53:04 GMT
– View all San Diego jobs
In cellular biology, molecular biology, genetics, or pharmacology (or a related discipline) and 5 or more years of industry experience in the area of in-vivo…
From DeviceSpace.com – 22 Jun 2016 06:52:59 GMT
– View all San Die…